Questions to Ask Before Proceeding with NanoACi

Why a structured conversation matters at this stage

Arriving at a consultation having already thought through the right questions changes the quality of the conversation. Rather than receiving a presentation, a prepared patient can test whether NanoACi is the right fit for their specific joint, at this point in their condition, given everything else going on in the joint.

NanoACi — Professor Paul Lee's surgeon-led, non-arthroscopic, needle-delivered, one-stage autologous chondrogenic injection technique — is a planned specialist procedure. Suitability is assessed individually through imaging, alignment, mechanical pathology, any ligament instability, and the patient's own goals. There is no universal candidate profile; the same grade of cartilage damage in two different joints, or two different people, may lead to different recommendations.

The five areas that follow — evidence, expected benefit, uncertainty, risks, and alternatives — are the questions that sit at the centre of any well-run pre-procedure conversation. Knowing them in advance means the answers a patient receives at consultation will be specific to their joint, not generic.

What the evidence actually shows — and what it doesn't yet

Three separate layers of published research underpin NanoACi — and understanding where one layer ends and the next begins is among the most useful things a patient can clarify before proceeding.

At the component level, the evidence is substantive. Auricular cartilage micrografting studies report reduced pain and improved function sustained over years. ChondroFiller, the native type I collagen scaffold, has randomised trial evidence against microfracture and more than a decade of multi-joint clinical use. Platelet-rich fibrin carries established mechanistic credentials as a sustained growth-factor signalling source. There is also published evidence for combining a regenerative cell source with a collagen scaffold — described in NanoACi documentation as the load-bearing logic of the protocol.

What does not yet exist is long randomised controlled trial data for the exact three-part NanoACi protocol — these micrografts, this scaffold, this fibrin, combined. The founder's own stated position is that the combined technique 'has not yet been through the long randomised trials that would allow it to be called proven as a whole.' That transparency is worth noting: it is the position of a clinician building evidence methodically rather than overstating it. Combined-protocol outcomes are being collected prospectively through the NanoACi 100 programme, and the founder acknowledges the evidence 'has to be built, patiently and honestly, over years.'

Component evidence cannot simply be transferred to support the whole protocol — these are distinct tiers, and any responsible assessment keeps them apart.

Questions worth raising at consultation

• What does the NanoACi 100 programme show so far for joints or lesion types similar to mine?
• When is trial-level combined-protocol data likely to be published, and what interim findings are available?
• How does the component evidence specifically apply to my joint, my lesion size, and my stage of wear?

What realistic benefit looks like for your specific situation

The clearest honest answer about expected benefit is this: no combined-protocol efficacy figure — no published success rate, no median improvement score — yet exists for NanoACi as a whole. The NanoACi 100 programme is designed to generate precisely that data, and what it shows for cases similar to a patient's own will be one of the most valuable things to ask about at consultation.

What the component evidence does offer, as a proxy, is meaningful. Micrografting studies report reduced pain and improved function sustained over years. The collagen scaffold has demonstrated results against microfracture in trial data. Those published signals represent the closest available indication of what the combined protocol is designed to achieve — though they cannot be read as efficacy data for NanoACi itself.

London Cartilage Clinic states directly that most patients are back to light daily activity the same day. That reflects the non-surgical access route — no operating theatre, no general anaesthetic — rather than a measured recovery outcome, but it is a real and practical distinction from arthroscopic alternatives.

Beyond procedure logistics, the clinic is explicit that 'individual results vary with the joint, the extent of wear, and your general health.' Lesion size, cartilage grade, the specific joint, and overall health each shape what functional improvement may realistically look like — which is precisely why generic benefit framing cannot substitute for a case-specific discussion.

Questions to raise at consultation

• What functional improvement is realistic for my lesion size, joint, and health status?
• How does my case compare to others the technique has been used on so far?
• What does the NanoACi 100 programme show for cases similar to mine, and when will fuller data be available?

Uncertainties that belong on the table

Three further gaps sit alongside the evidence picture already established — and all three are worth naming before a consultation rather than discovering afterwards.

First, specific contraindications for NanoACi are not formally published in available public sources. Suitability is determined through specialist case review, taking in factors such as joint alignment, ligament stability, mechanical pathology, imaging findings, and patient goals. That process is appropriate — cartilage cases are genuinely individual — but it means a patient cannot self-assess from a published list. The right question to ask is not only 'Am I suitable?' but also 'What would make me unsuitable, and does anything in my imaging or history point that way?'

Second, formal complication rates for the combined NanoACi protocol are not yet in the public record. Because all materials are autologous, theoretical immunological risk is low — no foreign biological substances are introduced — but that biological rationale is distinct from a reported adverse-event figure. Asking what complications have been observed to date, and how frequently, is a reasonable and answerable question for any emerging technique.

Third, NanoACi is performed at one centre — London Cartilage Clinic, 66 Harley Street — and is not NHS-funded. The procedure costs £8,000 (or £8,500 all-inclusive covering MRI, consultation, the single-session injection, and one follow-up), with physiotherapy quoted separately. Whether private health insurance will contribute varies by policy and is worth confirming before proceeding.

A specialist who is genuinely confident in the technique will answer all of these questions directly.

Questions to raise at consultation

• What specific factors would make me unsuitable for NanoACi?
• What complications have been observed so far, and how often?
• Is any part of this covered by my insurer, and what is the full cost including physiotherapy?

Risks worth naming in the room

The donor site question is worth addressing head-on. Three 2.5 mm punches taken from the concha of the ear under local anaesthetic represent the procedure's only tissue harvest; the resulting marks are hidden in the fold of the ear and heal within a week. For many patients this is the point of highest initial concern — and one of the more reassuring details once the scale is clear.

Because all three components — the auricular micrografts, the platelet-rich fibrin, and the collagen scaffold — derive from the patient's own body, no foreign biological substance is introduced. Theoretical immunological risk is accordingly low. That autologous profile is a clinically meaningful structural property of the technique, though it describes how the materials are sourced rather than constituting a reported safety figure.

The consultation is the right place to press for the risk picture specific to the combined protocol: how many patients have undergone NanoACi to date, what adverse events have been observed, and whether any factor in your history or imaging is associated with a less predictable result. These are standard informed-consent questions for any specialist procedure at this stage of outcome development.

Questions to raise at consultation

• What complications have been observed in patients who have had NanoACi, and how often?
• What would happen if the procedure did not achieve the intended result?
• Are there factors in my specific case that would increase risk?

How NanoACi compares to your other options

Cartilage pathways span a wide spectrum, and NanoACi sits at one point on it — not at every point. Understanding where the other options sit is what makes the specialist's recommendation meaningful rather than automatic.

At the less-invasive end, Mytocel MSK — the auricular micrograft component alone, without scaffold or platelet-rich fibrin — is available as a standalone treatment for earlier-stage cartilage wear. For some patients it represents an appropriate first step; for others, it may serve as a precursor, with the full NanoACi protocol considered at a later consultation if the clinical picture warrants it.

ACI and MACI are the established surgical comparators. Both are two-stage arthroscopic procedures with outcome records accumulated over decades; for many patients they remain the appropriate route, particularly where the clinical and imaging picture points toward a surgical approach. NanoACi does not replace them — it offers a non-arthroscopic lane for patients for whom that lane is genuinely suitable.

Microfracture is a simpler arthroscopic option. ChondroFiller alone suits certain patients without needing the full three-part combination. These distinctions matter because the right choice depends on lesion size, joint load, alignment, ligament stability, and degree of mechanical pathology — factors that may shift the recommendation toward established surgical routes regardless of how a patient feels about theatre.

At the other end of the spectrum, joint replacement remains clinically relevant for advanced disease and should feature in any honest comparative discussion.

The consultation is where imaging, history, and goals are weighed against all of these lanes. Arriving with a written list of your priorities — function, recovery time, avoiding surgery, cost, or some combination — gives that conversation a concrete starting point and helps Professor Lee map the options to your specific joint rather than to a general case.